Status:
COMPLETED
Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
HealthCore, Inc.
Conditions:
COPD Exacerbation
Eligibility:
All Genders
40+ years
Brief Summary
This study is intended to evaluate treatment effectiveness with budesonide/formoterol (BFC) and tiotropium tromide in patients new to ICS/LABA combination and LAMA therapies.
Detailed Description
Using US claims data from the HealthCore Integrated Research Environment, COPD patients ≥40 years old initiating BFC or tiotropium between 3/1/2009-2/28/2012 and considered at risk for a future exacer...
Eligibility Criteria
Inclusion
- Continuous health plan enrollment for 12 months before and after index Rx
- At least one prescription fill for BFC or tiotropium bromide during intake period, and naive to ICS/LABA combination or LAMA therapies in year prior to first prescription claim.
- COPD diagnosis, and aged 40 years of age at time of first prescription
- At risk population for COPD exacerbations
Exclusion
- ICS/LABA combination or LAMA therapy during pre-index period
- Patients with prescription claim for budesonide/formoterol and tiotropium bromide on the same day
- Patients diagnosed with cancer
- Patients with long-term OCS medication use during pre-index period
Key Trial Info
Start Date :
August 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
2396 Patients enrolled
Trial Details
Trial ID
NCT01917643
Start Date
August 1 2013
End Date
November 1 2013
Last Update
February 3 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.